CSNK1A1 and Miyoshi myopathy: Depletion/inhibition of CK1α is cytotoxic to MM cells but is dispensable for normal B cells and, importantly, synergizes with the clinically used proteasome inhibitors (bortezomib) and immune modulators (lenalidomide) [142].